Hello OVF.
Regarding phase 1 and 2 patients and ongoing supply. I asked Nina this specifically in a catch up and she said they'd love to, but if one of those patients had an issue, even if it wasn't associated with 200, it could risk the whole whole trial. So even though the company and shareholders would love it, the risk for all potential patients, company and shareholders if P3 is successful is too great.
Happy to be corrected, but that's my recollection of the discussion as I too was interested and remember feeling a bit sad, but understanding the bigger picture.
Thank you for your ongoing time and support for this forum and company.
keeping myself distracted before Friday lol. GLA
Cheers.
Dimerix (ASX: DXB) Discussion Thread, page-509
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.5¢ |
Change
-0.010(2.47%) |
Mkt cap ! $223.1M | |||
| Open | High | Low | Value | Volume |
| 40.5¢ | 40.5¢ | 39.3¢ | $137.4K | 346.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 160936 | 39.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 3205 | 2 |
View Market Depth
| Last trade - 11.57am 11/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |